Bone Metabolism and New Targets for Intervention

Overview

Journal Curr Urol Rep

Publisher Current Science

Specialty Urology

Date 2007 Apr 27

PMID 17459273

Authors

Bulent Akduman

E David Crawford

Affiliations

Soon will be listed here.

Abstract

Bone metastasis is a common complication of prostate cancer and is associated with significant morbidity for patients. Bone metabolism and prostate cancer metastasis to bone are complex processes. The interactions between host cells and metastatic prostate cancer cells are important components of organ-specific cancer progression. In addition to traditional treatment approaches, targeted therapy is currently becoming more popular. Bone metabolism, metastatic processes of prostate cancer, and the targeting of treatment for advanced disease are discussed here.

References

Stamenkovic I . Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol. 2003; 200(4):448-64. DOI: 10.1002/path.1400. View

Miwa S, Mizokami A, Keller E, Taichman R, Zhang J, Namiki M . The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer. Cancer Res. 2005; 65(19):8818-25. DOI: 10.1158/0008-5472.CAN-05-0540. View

Guise T, Yin J, Mohammad K . Role of endothelin-1 in osteoblastic bone metastases. Cancer. 2003; 97(3 Suppl):779-84. DOI: 10.1002/cncr.11129. View

Pfeilschifter J, Mundy G . Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci U S A. 1987; 84(7):2024-8. PMC: 304576. DOI: 10.1073/pnas.84.7.2024. View

Ebisawa T, Tada K, Kitajima I, Tojo K, Sampath T, Kawabata M . Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiation. J Cell Sci. 1999; 112 ( Pt 20):3519-27. DOI: 10.1242/jcs.112.20.3519. View

Tannock I, de Wit R, Berry W, Horti J, Pluzanska A, Chi K . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351(15):1502-12. DOI: 10.1056/NEJMoa040720. View

Koutsilieris M . Osteoblastic metastasis in advanced prostate cancer. Anticancer Res. 1993; 13(2):443-9. View

Kim J, Bae S, Choi J, Kim H, Ryoo H . The protein kinase C pathway plays a central role in the fibroblast growth factor-stimulated expression and transactivation activity of Runx2. J Biol Chem. 2002; 278(1):319-26. DOI: 10.1074/jbc.M203750200. View

Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T . Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun. 1998; 247(3):610-5. DOI: 10.1006/bbrc.1998.8697. View

10.

Festuccia C, Bologna M, Gravina G, Guerra F, Angelucci A, Villanova I . Osteoblast conditioned media contain TGF-beta1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components. Int J Cancer. 1999; 81(3):395-403. DOI: 10.1002/(sici)1097-0215(19990505)81:3<395::aid-ijc13>3.0.co;2-v. View

11.

Brown J, Vessella R, Kostenuik P, Dunstan C, Lange P, Corey E . Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res. 2001; 7(10):2977-83. View

12.

Kahn D, Weiner G, Ben-Haim S, Ponto L, Madsen M, Bushnell D . Positron emission tomographic measurement of bone marrow blood flow to the pelvis and lumbar vertebrae in young normal adults. Blood. 1994; 83(4):958-63. View

13.

Ferrer F, Miller L, Andrawis R, Kurtzman S, Albertsen P, Laudone V . Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol. 1997; 157(6):2329-33. View

14.

Simonet W, Lacey D, Dunstan C, Kelley M, Chang M, Luthy R . Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89(2):309-19. DOI: 10.1016/s0092-8674(00)80209-3. View

15.

Sano M, Kushida K, Takahashi M, Ohishi T, Kawana K, Okada M . Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastasis. Br J Cancer. 1994; 70(4):701-3. PMC: 2033391. DOI: 10.1038/bjc.1994.377. View

16.

Rabbani S, DesJardins J, Bell A, Banville D, Mazar A, Henkin J . An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Commun. 1990; 173(3):1058-64. DOI: 10.1016/s0006-291x(05)80893-9. View

17.

Roodman G . Cell biology of the osteoclast. Exp Hematol. 1999; 27(8):1229-41. DOI: 10.1016/s0301-472x(99)00061-2. View

18.

Corey E, Brown L, Quinn J, Poot M, Roudier M, Higano C . Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res. 2003; 9(1):295-306. View

19.

Edlund M, Miyamoto T, Sikes R, Ogle R, Laurie G, Farach-Carson M . Integrin expression and usage by prostate cancer cell lines on laminin substrata. Cell Growth Differ. 2001; 12(2):99-107. View

20.

Funa K, Eriksson B, Wilander E, Oberg K . In situ hybridization study of chromogranin A and B mRNA in carcinoid tumors. Histochemistry. 1991; 95(6):555-9. DOI: 10.1007/BF00266741. View